Suppr超能文献

在局部晚期直肠癌患者术前放化疗后,病理分期对无病生存期的预后价值最大。

Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation.

作者信息

Quah Hak-Mien, Chou Joanne F, Gonen Mithat, Shia Jinru, Schrag Deborah, Saltz Leonard B, Goodman Karyn A, Minsky Bruce D, Wong W Douglas, Weiser Martin R

机构信息

Department of Colorectal Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

出版信息

Cancer. 2008 Jul 1;113(1):57-64. doi: 10.1002/cncr.23516.

Abstract

BACKGROUND

Preoperative chemoradiation is the standard treatment for locally advanced rectal cancer. However, it is uncertain whether pretreatment clinical stage, degree of response to neoadjuvant treatment, or pathologic stage is the most reliable predictor of outcome. This study compared various staging elements and treatment-related variables to identify which factors or combination of factors reliably prognosticates disease-free survival in rectal cancer patients receiving neoadjuvant combined modality therapy.

METHODS

From a prospectively maintained single institution database, 342 consecutive patients with locally advanced rectal cancer staged by endorectal ultrasound were identified. Patients underwent rectal resection 4 to 8 weeks after a 5.5-week course of pelvic radiotherapy/concurrent chemotherapy. The degree of tumor regression was histologically graded on each resected specimen using a previously reported response scale of 0% to 100%. Predictive models of disease-free survival were created utilizing available pretherapy and postoperative staging elements in addition to the degree of tumor regression noted histologically. Model accuracy was measured and compared by concordance index, with 95% confidence interval (CI).

RESULTS

Stratifying patients by degree of tumor regression predicted outcome with a concordance index of 0.65 (95% CI, 0.59-0.71), which was significantly better than models using preoperative stage elements (concordance index of 0.54; 95% CI, 0.50-0.58). However, the model found to be most predictive of disease-free survival stratified patients by final pathologic T classification and N classification elements, with a concordance index of 0.75 (95% CI, 0.70-0.80).

CONCLUSIONS

Tumor response to preoperative therapy is a strong predictor of disease-free survival. However, outcome is most accurately estimated by final pathologic stage, which is influenced by both preoperative stage and response to therapy.

摘要

背景

术前放化疗是局部晚期直肠癌的标准治疗方法。然而,术前临床分期、对新辅助治疗的反应程度或病理分期是否是最可靠的预后预测指标尚不确定。本研究比较了各种分期因素和与治疗相关的变量,以确定哪些因素或因素组合能可靠地预测接受新辅助联合治疗的直肠癌患者的无病生存期。

方法

从一个前瞻性维护的单机构数据库中,确定了342例经直肠内超声分期的局部晚期直肠癌连续患者。患者在接受5.5周的盆腔放疗/同步化疗后4至8周接受直肠切除术。使用先前报道的0%至100%的反应量表,对每个切除标本的肿瘤消退程度进行组织学分级。除了组织学记录的肿瘤消退程度外,还利用可用的治疗前和术后分期因素建立了无病生存期的预测模型。通过一致性指数测量并比较模型准确性,95%置信区间(CI)。

结果

根据肿瘤消退程度对患者进行分层,预测结果的一致性指数为0.65(95%CI,0.59 - 0.71),显著优于使用术前分期因素的模型(一致性指数为0.54;95%CI,0.50 - 0.58)。然而,发现最能预测无病生存期的模型是根据最终病理T分类和N分类因素对患者进行分层,一致性指数为0.75(95%CI,0.70 - 0.80)。

结论

肿瘤对术前治疗的反应是无病生存期的有力预测指标。然而,最终病理分期最准确地估计了预后,其受术前分期和治疗反应的影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验